Comparing the current results to its competitors, Biomerica Inc reported Revenue increase in the 4 quarter 2026 by 16.96 % year on year. The sales growth was above Biomerica Inc 's competitors' average revenue growth of 7.72 %, achieved in the same quarter.
Biomerica Inc 's Comment on Competition and Industry Peers
Biomerica develops proprietary diagnostic products, including the EZ Detect colon disease home test, the Aware Breast Self-Exam product, the inFoods® IBS product, and hp+detect™ for H. pylori detection. The company competes with divisions and subsidiaries of larger medical and pharmaceutical firms that invest significantly more in research and development, manufacturing, advertising, and marketing. Biomerica also offers contract development and manufacturing services, competing based on technical capabilities, quality, pricing, service, and project execution. The competitive environment is influenced by factors such as product uniqueness, technology, quality, performance, pricing, and service. Biomerica's competitive position is supported by the distinctiveness of its products, the quality and speed of its test results, and its patent portfolio.
Overall company sales advanced by 16.96 % Biomerica Inc outperformed its competitors in this segment and improved market share, to approx. 0.02 %. << More on BMRA Market Share.
*Market share is calculated based on total revenue.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Abbott Laboratories operates as a diversified healthcare company with a focus on developing and manufacturing a wide range of health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. Their business model emphasizes innovation and quality, aiming to address the diverse needs of patients and healthcare providers across various sectors globally. By leveraging their expertise and extensive portfolio, Abbott strives to enhance patient outcomes and improve the overall quality of life.
Caredx Inc is a precision medicine company with a business model focused on transplant diagnostics. They develop and commercialize non-invasive tests to identify and monitor organ transplant rejection. By offering innovative solutions and services in the transplant field, Caredx Inc aims to improve outcomes for patients and provide healthcare professionals with valuable information to guide treatment decisions.
Quest Diagnostics Inc operates as a leading provider of clinical laboratory and diagnostic information services, catering to patients, healthcare professionals, hospitals, and pharmaceutical companies. The company generates revenue through a comprehensive suite of diagnostic testing services, encompassing routine lab tests, advanced molecular diagnostics, and a variety of specialized tests tailored to support clinical decision-making and patient care.
Fulgent Genetics Inc is a genetic testing company that offers comprehensive, flexible, and affordable genetic testing solutions for various applications, including clinical diagnostics, carrier screening, and genetic research.
Sources:
Biomerica Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biomerica Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
